Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027

        4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook

    5.1. Innovative Solutions for COPD Treatment

    5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        6.3.1. Combination Therapy 

            6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            6.3.1.3. Triple Therapy

            6.3.1.4. Others

        6.3.2. Corticosteroids

        6.3.3. Bronchodilators

            6.3.3.1. Long Acting Beta Agonist (LABA)

            6.3.3.2. Short Acting Beta Agonist (SABA)

            6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)

        6.3.4. Phosphodiesterase Type 4 Inhibitors

        6.3.5. Mucokinetics

        6.3.6. Others

    6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class 

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel 

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        9.2.1. Combination Therapy 

            9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            9.2.1.3. Triple Therapy

            9.2.1.4. Others

        9.2.2. Corticosteroids

        9.2.3. Bronchodilators

            9.2.3.1. Long Acting Beta Agonist (LABA)

            9.2.3.2. Short Acting Beta Agonist (SABA)

            9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        9.2.4. Phosphodiesterase Type 4 Inhibitors

        9.2.5. Mucokinetics

        9.2.6. Others

    9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By Distribution Channel 

        9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.2.1. Combination Therapy 

            10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            10.2.1.3. Triple Therapy

            10.2.1.4. Others

        10.2.2. Corticosteroids

        10.2.3. Bronchodilators

            10.2.3.1. Long Acting Beta Agonist (LABA)

            10.2.3.2. Short Acting Beta Agonist (SABA)

            10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        10.2.4. Phosphodiesterase Type 4 Inhibitors

        10.2.5. Mucokinetics

        10.2.6. Others

    10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Russia

        10.4.7. Rest of Europe

    10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By Distribution Channel 

        10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.2.1. Combination Therapy 

            11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            11.2.1.3. Triple Therapy

            11.2.1.4. Others

        11.2.2. Corticosteroids

        11.2.3. Bronchodilators

            11.2.3.1. Long Acting Beta Agonist (LABA)

            11.2.3.2. Short Acting Beta Agonist (SABA)

            11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        11.2.4. Phosphodiesterase Type 4 Inhibitors

        11.2.5. Mucokinetics

        11.2.6. Others

    11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By Distribution Channel 

        11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.2.1. Combination Therapy 

            12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            12.2.1.3. Triple Therapy

            12.2.1.4. Others

        12.2.2. Corticosteroids

        12.2.3. Bronchodilators

            12.2.3.1. Long Acting Beta Agonist (LABA)

            12.2.3.2. Short Acting Beta Agonist (SABA)

            12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        12.2.4. Phosphodiesterase Type 4 Inhibitors

        12.2.5. Mucokinetics

        12.2.6. Others

    12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Distribution Channel 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.2.1. Combination Therapy 

            13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            13.2.1.3. Triple Therapy

            13.2.1.4. Others

        13.2.2. Corticosteroids

        13.2.3. Bronchodilators

            13.2.3.1. Long Acting Beta Agonist (LABA)

            13.2.3.2. Short Acting Beta Agonist (SABA)

            13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        13.2.4. Phosphodiesterase Type 4 Inhibitors

        13.2.5. Mucokinetics

        13.2.6. Others

    13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC 

        13.4.2. South Africa

        13.4.3. Israel

        13.4.4. Rest of Middle East & Africa

    13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By Distribution Channel 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)

    14.3. Company Profiles

        14.3.1. AstraZeneca 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Boehringer Ingelheim International GmbH

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. GlaxoSmithKline plc 

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Novartis AG 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Teva Pharmaceutical Industries Ltd. 

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.) 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. CHIESI Farmaceutici S.p.A. 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Orion Corporation 

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Mylan N.V.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis